IMC.AX - Immuron Limited

ASX - ASX Delayed Price. Currency in AUD

Immuron Limited

Unit 10
25?37 Chapman Street
Blackburn North, VIC 3130
61 3 9824 5254

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Jerry Kanellos Ph.D.Interim CEO175.2kN/A1961
Mr. Peter AnastasiouExec. Vice Chairman42.5kN/A1960
Mr. Phillip Allen HainsJoint CFO & Company Sec.N/AN/A1959
Mr. Peter Vaughan BBus(Acc), CAJoint CFO & Company Sec.N/AN/A1983
Mr. David LyonHead of MarketingN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for NASH and ASH. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research; and Naval Medical Research Center. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia.

Corporate Governance

Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.